CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of GeneDx, Inc. to Sema4 Holdings Corp. (“the Company”) (NasdaqGS: SMFR). Under the terms of the proposed transaction, Sema4 will acquire GeneDx for a total upfront consideration of approximately $473 million, and a total aggregate consideration including potential milestones of approximately $623 million, based on the closing stock price of Sema4 as of January 14, 2022. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or visit https://kclasslaw.com/cases/ma/nasdaqgs-smfr/ to learn more.
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.
